system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Animals, Cell Adhesion, Cell Movement, Cell Proliferation, Cells, Cultured, Disease Models, Animal, Gene Expression, Genetic Therapy, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating), Humans, Pigment Epithelium of Eye, Protein Kinases, RNA, Messenger, RNA, Small Interfering, Rabbits, Retinal Detachment, Reverse Transcriptase Polymerase Chain Reaction, TOR Serine-Threonine Kinases, Transfection, Vitreoretinopathy, Proliferative.
user
Does siRNA targeting mammalian target of rapamycin ( mTOR ) attenuate experimental proliferative vitreoretinopathy? Context: To investigate the effect of mammalian target of rapamycin (mTOR) specific siRNA on proliferative vitreoretinopathy (PVR). Cultured human retinal pigment epithelial (hRPE) cell line D407 was treated with three mTOR specific small interfering RNAs. Cell proliferation, attachment, spreading, and migration were performed. The impact of the mTOR specific siRNA on PVR was tested using a rabbit model in which PVR was induced by the injection of hRPE cells. Decreasing mTOR expression by about 82% using small interfering RNA resulted in a significant decrease in cell spreading and migration. Whereas retinal detachment occurred in 100% of the control group animals, co-injection of the mTOR specific siRNA substantially reduced the severity and incidence (50%) of retinal detachments.
assistant
Gene therapy with mTOR specific siRNA attenuates PVR in a rabbit model of the disease. This may be a new approach to preventing PVR in humans. Final Decision: yes